November 27, 2024 — Yesterday, Amgen released topline data on their remarkable monthly obesity medicine – MariTide or maridebart cafraglutide. To us, the results are impressive, albeit preliminary. In 52 weeks of study, patients with obesity or overweight lost approximately 20% of their initial body weight and even after a year, they appeared to still be losing weight. For […]
April 26, 2024 — Perhaps the most persistent fault that people find with new obesity medicines is the need to keep taking them forever. “Nobody is ready ” for that, says Business Insider. “Patients hate forever drugs,” says the New York Times. And they have a point. Obesity medicine doctors are quick to say “suck it up.” That’s just […]
February 6, 2024 — We learned recently that questions about the need for ongoing dosing with obesity medicines raise discomforting thoughts. After all, obesity is a chronic disease, so we can’t dispute the need for continued daily or weekly doses with obesity medicines. Or can we? Amgen seems to think we can. Monthly Dosing? Induction and Maintenance? With a […]
December 5, 2022 — Move over, Novo Nordisk and Eli Lilly. Amgen wants a piece of the action in obesity treatment. With some obvious pride of accomplishment, Amgen unveiled results from a phase 1 study of its dual action conjugate on Saturday. This new experimental drug, AMG 133, is a molecule that combines peptides to activate GLP-1 receptors (as […]
October 23, 2017 — It’s early days for this new protein, but worth noting, nonetheless. Amgen scientists have successfully demonstrated that they can modify a GDF15 protein to treat obesity in mice, rats, and primates. With animal data published in Science Translational Medicine, they show an impressive effect on body weight in mice and monkeys. Acting on the Gut […]
